Athira pharma to present overview and update from act-ad phase 2 trial of fosgonimeton (ath-1017) in mild-to-moderate alzheimer's disease at ad/pd™ 2022 congress

Bothell, wash., march 14, 2022 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that an overview and update of the fully enrolled act-ad phase 2 clinical trial with athira's lead development candidate fosgonimeton (ath-1017) in mild-to-moderate alzheimer's disease, will be presented at the international conference on alzheimer's & parkinson diseases™ 2022, ad/pd™ 2022 hybrid​ congress, taking place march 15-20, 2022 virtually and in barcelona.
ATHA Ratings Summary
ATHA Quant Ranking